Molecure (MOC) Q4 2025 earnings summary

Executive summary

• Report covers the period from 01.01.2025 to 31.12.2025, with comparative data for 2024.

• Main activity is R&D of small-molecule drugs for high unmet clinical needs, especially oncology and respiratory diseases.

• The company operates under a business model with delayed revenue recognition, resulting in a net loss for the year.

• No material uncertainty regarding going concern; management expects continued operations for at least 12 months.

Financial highlights

• Operating revenue: PLN 6.52 million in 2025, up from PLN 2.15 million in 2024.

• Net loss: PLN 15.69 million in 2025, significantly reduced from PLN 31.53 million in 2024.

• Operating loss: PLN 16.56 million in 2025, improved from PLN 32.33 million in 2024.

• Cash and equivalents at year-end: PLN 16.35 million (down from PLN 17.90 million in 2024).

• Total assets: PLN 94.43 million at 31.12.2025 (down from PLN 113.44 million at 31.12.2024).

• Equity: PLN 87.45 million at year-end (down from PLN 103.13 million in 2024).

• Basic and diluted loss per share: PLN -0.76 (improved from PLN -1.56 in 2024).

Outlook and guidance

• Focus remains on advancing clinical-stage programs and optimizing cost structure.

• Strategic shift to concentrate resources on key clinical programs with highest commercial potential.